Brooklyn ImmunoTherapeutics, Inc.·4

Aug 20, 1:38 PM ET

DENNY GEORGE P III 4

4 · Brooklyn ImmunoTherapeutics, Inc. · Filed Aug 20, 2021

Insider Transaction Report

Form 4
Period: 2021-07-06
Transactions
  • Sale

    Common Stock

    2021-07-06$16.06/sh75,000$1,204,6884,775,117 total(indirect: By LLC)
  • Purchase

    Common Stock

    2021-07-08$14.35/sh+1$141 total(indirect: By Spouse)
  • Purchase

    Common Stock

    2021-07-09$14.11/sh+1$142 total(indirect: By Spouse)
  • Purchase

    Common Stock

    2021-07-14$11.99/sh+1$123 total(indirect: By Spouse)
Holdings
  • Common Stock

    4,094
  • Common Stock

    (indirect: By Trust)
    34,585
Footnotes (3)
  • [F1]The sale by Denny Family Partners II, LLC of BTX Common Stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 3 shares, with the purchase of 3 shares of BTX Common Stock by the reporting person's spouse, also reported herein. The reporting person has agreed to pay to BTX, upon settlement of the sale, $8.78, representing the full amount of the profit realized in connection with the short-swing transaction, less transaction costs.
  • [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.41, inclusive. The reporting person undertakes to provide to Brooklyn ImmunoTherapeutics, Inc., any security holder of Brooklyn ImmunoTherapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2.
  • [F3]The reporting person disclaims beneficial ownership of the shares held by Denny Family Partners II, LLC except to the extent of his pecuniary interest therein.

Documents

1 file
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES